Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.42 |
| ▸ | WNT3A | P56704 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31901342 | 0.84 | ERCC5 (0.60) | ERCC5FEN1CTNNB1WNT3ANPC1 | |
| SCHEMBL364889 | 0.84 | ERCC5 (0.60) | ERCC5FEN1CTNNB1WNT3ANPC1 | |
| SCHEMBL1792140 | 0.81 | ERCC5 (0.56) | ERCC5FEN1CTNNB1WNT3ANPC1 | |
| Piperidine SCHEMBL15967083 | 0.80 | ALDH1A1 (0.44) | NPC1RAB9AHTTSLC6A2SLC6A4 | |
| Propiophenone SCHEMBL27835084 | 0.78 | MAPT (0.55) | NPC1RAB9AHTTOPRM1 | |
| Propiophenone SCHEMBL28050246 | 0.77 | MAPT (0.53) | NPC1RAB9AHTTOPRM1 | |
| Formamide SCHEMBL8020659 | 0.76 | ERCC5 (0.51) | ERCC5FEN1CTNNB1WNT3ANPC1 | |
| O-Xylene SCHEMBL28069090 | 0.74 | TSHR (0.53) | OPRM1 | |
| Piperidine SCHEMBL7617785 | 0.72 | CLCN2 (0.46) | HTTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13990159 | 0.72 | L3MBTL1 (0.52) | ERCC5FEN1HTTABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770636-B2 | CENTRAL NERVOUS SYSTEM DISORDERS THERAPY | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-08-03 | — | — | US | disclosed |
| US-20020042410-A1 | Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042410-A1 | Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines | AOC2, CYC1, CYCS | ERCC5 971/4885FEN1 1591/4885CTNNB1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.